University of Dundee

Latest News for 09/2021

July 2021

  • Professor Alessio Ciulli
    19 Jul 2021

    The expansion of an exemplary industry-academia collaboration will see the University of Dundee, in partnership with Boehringer Ingelheim, intensify its efforts to develop new medicines that target and destroy key cancer-causing proteins, which have previously been regarded as undruggable.

April 2021

  • Artist impression of Centre for Targeted Protein Degradation lab
    14 Apr 2021

    A new translational research centre will bolster the University of Dundee’s world-leading position in a field of chemical biology that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.

March 2021

  • Pic show Professors Alessio Ciulli (L) and Sir Mike Ferguson (R)
    17 Mar 2021

    Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases. Amphista is a biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins. The company is a spinout from Professor Alessio Ciulli’s labs at the University’s School of Life Sciences.

  • From left: Angus Cowan, Claudia Diehl and Angela Harrison
    10 Mar 2021

    In the recent round of applications for Marie Skłodowska-Curie Fellowships, the School had a 100% success rate! Over the coming months, three scientists from across the globe will commence their new research projects. Angus Cowan from Melbourne, Australia and Claudia Diehl from Aachen, Germany will join Professor Alessio Ciulli’s lab while Angela Harrison, also from Melbourne, will join Professor Angus Lamond’s team.

November 2020

October 2020

  • Professor Alessio Ciulli
    08 Oct 2020

    The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need. The collaboration will accelerate the discovery of innovative medicines by bringing together Almirall’s expertise in dermatology with the world-leading work of Professor Alessio Ciulli, from the University’s School of Life Sciences.

July 2020

  • Dr Gopal Sapkota
    15 Jul 2020

    University of Dundee researchers have demonstrated a new method of destroying an ‘undruggable’ protein known to play a role in cancer, raising the possibility of a new therapeutic approach to the disease. Mutations of the K-Ras protein have long been known to cause many cancers, including lung, colorectal, and pancreatic cancers, but despite decades of work by researchers across the world, an inhibitor for this protein has proven elusive. As a result, scientists have increasingly looked to novel ways of targeting K-Ras.

June 2020

  • EUbOPEN logo
    08 Jun 2020

    Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes are well-characterized small chemical modulators of protein function. The newly formed public-private partnership “Enabling and Unlocking biology in the OPEN” (EUbOPEN) aims to develop high quality chemical tool compounds for 1,000 proteins (one third of the druggable proteins in the human body).

May 2020

  • 18 May 2020

    Proteolysis-targeting chimera (PROTAC) compounds developed at the University of Dundee are being made available free of charge by the pharmaceutical company Boehringer Ingelheim through their scientific crowdsourcing platform opnMe.com. The opnMe portal provides free and open access to selected molecules for the scientific community aiming at accelerating research initiatives that can benefit patients with high unmet medical need.

April 2020

  • Professor Alessio Ciulli
    07 Apr 2020

    A University of Dundee spinout has announced a multi-million pound deal to develop first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins.

Pages